SEC Form SC 13G/A filed by Rallybio Corporation (Amendment)
$RLYB
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/9/2025 | Buy → Neutral | H.C. Wainwright | |
| 5/15/2024 | Overweight → Neutral | JP Morgan | |
| 2/7/2024 | $7.00 → $1.50 | Buy → Hold | Jefferies |
| 4/17/2023 | $18.00 | Buy | H.C. Wainwright |
| 4/10/2023 | $17.00 | Outperform | Wedbush |
| 12/9/2022 | $21.00 | Overweight | JP Morgan |
| 2/22/2022 | $32.00 | Mkt Outperform | JMP Securities |
| 8/23/2021 | $40.00 | Outperform | Evercore ISI Group |
S-8 - Rallybio Corp (0001739410) (Filer)
10-Q - Rallybio Corp (0001739410) (Filer)
8-K - Rallybio Corp (0001739410) (Filer)
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
4 - Rallybio Corp (0001739410) (Issuer)
– On Track to Initiate Dosing in RLYB116 Confirmatory PK/PD Study in 2Q 2025, with Multiple Data Readouts Anticipated in 2H 2025 – – $54.5 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2025 Provides Runway into 1H 2027 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported first quarter financial results for the period ended March 31, 2025, and provided an update on recent company developments. "We are focused on advancing RLYB116 into a confirmatory pharmacokinetic/pharmacodynamic study this quarter, and believe th
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that Stephen Uden, M.D., Chief Executive Officer of Rallybio, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Wednesday, May 7, 2025 at 12:00 p.m. ET in New York, NY. A live webcast of the fireside chat will be accessible through the Events and Presentations section of Rallybio's website at www.rallybio.com. An archived replay of the webcast will be available for 30 days following the presentation. About Rallybio Rallybio (NASDAQ:RLYB) is a clinical-stage bi
– RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy – – RLYB116 Confirmatory PK/PD Study to Initiate in 2Q 2025, with Data in 2H 2025 – Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the discontinuation of the RLYB212 program for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The Company's decision to discontinue RLYB212 development was based on pharmacokinetic (PK) data from the Phase 2 clinical trial demonstrating the inability of the R
SC 13G/A - Rallybio Corp (0001739410) (Subject)
SC 13G - Rallybio Corp (0001739410) (Subject)
SC 13G/A - Rallybio Corp (0001739410) (Subject)
H.C. Wainwright downgraded Rallybio from Buy to Neutral
JP Morgan downgraded Rallybio from Overweight to Neutral
Jefferies downgraded Rallybio from Buy to Hold and set a new price target of $1.50 from $7.00 previously
-- 100 mg Results Demonstrated a Mean Reduction of Greater than 93% in Free C5 with Low Volume Once-a-Week Subcutaneous Dosing -- -- Data Supports the Study of RLYB116 as a Differentiated Therapeutic for the Treatment of Generalized Myasthenia Gravis -- -- Company Announces Extension of Runway to 3Q 2025 As Part of Portfolio Prioritization -- -- Conference Call and Webcast Today at 8:30 AM Eastern Time -- Rallybio Corporation (NASDAQ:RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated disea
-- Martin Mackay, Ph.D., CEO, Chairman of the Board and Co-Founder of Rallybio To Become Executive Chairman -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Stephen Uden, M.D., Rallybio's President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1, 2023. Dr. Uden will remain President and will also be appointed to Rallybio's Board of Directors. The Company does not expect to hire a replacement for Dr. Uden's current role. He will succeed Mart
-- Proof-of-Concept Achieved for RLYB212; Showed Rapid and Complete Elimination of Transfused HPA-1a Positive Platelets in HPA-1a Negative Subjects -- -- Phase 1 Multiple Dose Cohort RLYB212 Study Initiated -- -- Phase 1 Multiple Ascending Dose Study of RLYB116 Continues to Progress; Safety, PK and PD Data Expected in 4Q 2023 -- -- $169.0 million cash, cash equivalents and marketable securities as of December 31, 2022; Provides Runway into 1Q 2025 -- Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Jonathan I. Lieber will join as the Company's Chief Financial Officer (CFO), effective February 1, 2023. Mr. Lieber succeeds Jeffrey Fryer, CPA, Rallybio's Co-Founder and CFO. The company announced Mr. Fryer's departure in June 2022, and following a transition period with Mr. Lieber, Mr. Fryer will depart the company on February 15, 2023. Mr. Lieber brings more than 30 years of experience as a CFO for public and private life sciences companies and an investment ban